دورية أكاديمية
Comparing adults with severe SARS-CoV-2 or influenza infection: South Africa, 2016-2021.
العنوان: | Comparing adults with severe SARS-CoV-2 or influenza infection: South Africa, 2016-2021. |
---|---|
المؤلفون: | Els F; Centre for Respiratory Diseases and Meningitis, National Institute for Communicable Diseases (NICD) of the National Health Laboratory Service (NHLS), Johannesburg, South Africa.; South African Field Epidemiology Training Programme (SAFETP), Division of Public Health, Surveillance and Response (DPHSR), National Institute for Communicable Diseases (NICD) of the National Health Laboratory Service (NHLS), Johannesburg, South Africa.; School of Health Systems and Public Health, Faculty of Health Sciences, University of Pretoria, Pretoria, South Africa., Kleynhans J; Centre for Respiratory Diseases and Meningitis, National Institute for Communicable Diseases (NICD) of the National Health Laboratory Service (NHLS), Johannesburg, South Africa.; School of Public Health, Faculty of Health Sciences, University of the Witwatersrand, Johannesburg, South Africa., Wolter N; Centre for Respiratory Diseases and Meningitis, National Institute for Communicable Diseases (NICD) of the National Health Laboratory Service (NHLS), Johannesburg, South Africa.; School of Pathology, Faculty of Health Sciences, University of the Witwatersrand, Johannesburg, South Africa., du Plessis M; Centre for Respiratory Diseases and Meningitis, National Institute for Communicable Diseases (NICD) of the National Health Laboratory Service (NHLS), Johannesburg, South Africa.; School of Pathology, Faculty of Health Sciences, University of the Witwatersrand, Johannesburg, South Africa., Moosa F; Centre for Respiratory Diseases and Meningitis, National Institute for Communicable Diseases (NICD) of the National Health Laboratory Service (NHLS), Johannesburg, South Africa.; School of Pathology, Faculty of Health Sciences, University of the Witwatersrand, Johannesburg, South Africa., Tempia S; Centre for Respiratory Diseases and Meningitis, National Institute for Communicable Diseases (NICD) of the National Health Laboratory Service (NHLS), Johannesburg, South Africa.; School of Public Health, Faculty of Health Sciences, University of the Witwatersrand, Johannesburg, South Africa., Makhasi M; Centre for Respiratory Diseases and Meningitis, National Institute for Communicable Diseases (NICD) of the National Health Laboratory Service (NHLS), Johannesburg, South Africa., Nel J; Department of Medicine, Faculty of Health Sciences, University of the Witwatersrand, Johannesburg, South Africa., Dawood H; Department of Medicine, Greys Hospital, Pietermaritzburg and Centre for the Aids programme of research in South Africa, University of KwaZulu-Natal, Pietermaritzburg, South Africa., Meiring S; Division of Public Health Surveillance and Response, National Institute for Communicable Diseases of the National Health Laboratory Service, Johannesburg, South Africa., von Gottberg A; Centre for Respiratory Diseases and Meningitis, National Institute for Communicable Diseases (NICD) of the National Health Laboratory Service (NHLS), Johannesburg, South Africa.; School of Pathology, Faculty of Health Sciences, University of the Witwatersrand, Johannesburg, South Africa., Cohen C; Centre for Respiratory Diseases and Meningitis, National Institute for Communicable Diseases (NICD) of the National Health Laboratory Service (NHLS), Johannesburg, South Africa.; School of Public Health, Faculty of Health Sciences, University of the Witwatersrand, Johannesburg, South Africa., Walaza S; Centre for Respiratory Diseases and Meningitis, National Institute for Communicable Diseases (NICD) of the National Health Laboratory Service (NHLS), Johannesburg, South Africa.; School of Public Health, Faculty of Health Sciences, University of the Witwatersrand, Johannesburg, South Africa. |
المصدر: | Southern African journal of infectious diseases [S Afr J Infect Dis] 2024 Jul 26; Vol. 39 (1), pp. 574. Date of Electronic Publication: 2024 Jul 26 (Print Publication: 2024). |
نوع المنشور: | Journal Article |
اللغة: | English |
بيانات الدورية: | Publisher: AOSIS Publishing Country of Publication: South Africa NLM ID: 101646666 Publication Model: eCollection Cited Medium: Internet ISSN: 2313-1810 (Electronic) Linking ISSN: 23120053 NLM ISO Abbreviation: S Afr J Infect Dis Subsets: PubMed not MEDLINE |
أسماء مطبوعة: | Publication: 2019- : Durbanville, Cape Town, South Africa : AOSIS Publishing Original Publication: [Centurion] : Medpharm Publications (Pty) Ltd., 2014- |
مستخلص: | Background: Comparisons of the characteristics of individuals hospitalised with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) or seasonal influenza in low-to middle-income countries with high human immunodeficiency virus (HIV) prevalence are limited. Objectives: Determine the epidemiological differences with those hospitalised with influenza or SARS-CoV-2 infection. Method: We investigated hospitalised individuals ≥18 years of age testing positive for seasonal influenza (2016-2019) or SARS-CoV-2 (2020-2021). We used random effects multivariable logistic regression, controlling for clustering by site, to evaluate differences among adults hospitalised with influenza or SARS-CoV-2 infection. Results: Compared to individuals with influenza, individuals with SARS-CoV-2 infection were more likely to be diabetic (adjusted odds ratio [aOR]: 1.70, 95% confidence interval [CI]: 1.11-2.61) or die in hospital (aOR: 2.57, 95% CI: 1.61-4.12). Additionally, those with SARS-CoV-2 infection were less likely to be living with HIV (not immunosuppressed) (aOR: 0.50, 95% CI: 0.34-0.73) or living with HIV (immunosuppressed) (aOR: 0.27, 95% CI: 0.18-0.39) compared to not living with HIV and less likely to be asthmatic (aOR: 0.21, 95% CI: 0.13-0.33) rather than those living with influenza. Conclusion: Individuals hospitalised with SARS-CoV-2 had different characteristics to individuals hospitalised with influenza before the coronavirus disease 2019 (COVID-19) pandemic. Risk factors should be considered in health management especially as we move into an era of co-circulation of SARS-CoV-2 and influenza pathogens. Contribution: Identifying groups at high risk of severe disease could help to better monitor, prevent and control SARS-CoV-2 or influenza severe disease. Competing Interests: S.M. received an investigational grant from Sanofi Pasteur unrelated to this research. N.W. and A.v.G. received funding from Sanofi, US CDC and the Bill and Melinda Gates Foundation. C.C. has received funding from the Wellcome Trust and US CDC related to this work and PATH, South African Medical Research Council, Sanofi, and the Bill and Melinda Gates Foundation unrelated to this work. S.W. has received funding from US CDC related to this work. M.d.P. has received funding from the Bill and Melinda Gates foundation and the National Research Foundation, South Africa, unrelated to this work. (© 2024. The Authors.) |
References: | Lancet Glob Health. 2021 Jun;9(6):e863-e874. (PMID: 34019838) J Gen Intern Med. 2021 Jun;36(6):1689-1695. (PMID: 33738759) Infect Dis (Lond). 2021 Feb;53(2):111-121. (PMID: 33170050) Influenza Other Respir Viruses. 2019 Sep;13(5):484-495. (PMID: 31187609) Lancet HIV. 2021 Sep;8(9):e554-e567. (PMID: 34363789) Pediatr Infect Dis J. 2015 Jan;34(1):66-72. (PMID: 25093972) Emerg Infect Dis. 2013 Nov;19(11):1766-74. (PMID: 24209781) Clin Infect Dis. 2021 Oct 5;73(7):e2005-e2015. (PMID: 32860699) Diagnostics (Basel). 2021 Jun 13;11(6):. (PMID: 34199257) PLoS One. 2015 Mar 18;10(3):e0118884. (PMID: 25786103) Open Forum Infect Dis. 2022 Nov 02;9(12):ofac578. (PMID: 36570970) Ann Am Thorac Soc. 2021 Apr;18(4):632-640. (PMID: 33183067) Open Forum Infect Dis. 2019 Mar 19;6(3):ofz020. (PMID: 30906797) Ann Am Thorac Soc. 2020 Dec;17(12):1645-1648. (PMID: 32864985) Lancet Respir Med. 2021 Mar;9(3):251-259. (PMID: 33341155) Clin Obes. 2020 Dec;10(6):e12403. (PMID: 32857454) Curr Opin Immunol. 2013 Aug;25(4):470-6. (PMID: 23948572) J Infect Dis. 2013 Dec 15;208 Suppl 3:S217-26. (PMID: 24265481) Diabetes Metab Res Rev. 2021 Feb;37(2):e3377. (PMID: 32588943) Euro Surveill. 2020 Jan;25(3):. (PMID: 31992387) Cells. 2021 Apr 17;10(4):. (PMID: 33920604) BMJ Nutr Prev Health. 2022 Jan 19;5(1):10-18. (PMID: 35814718) Cold Spring Harb Perspect Med. 2021 Nov 1;11(11):. (PMID: 32988981) J Infect Dis. 2012 Nov;206(9):1350-8. (PMID: 23002448) Front Cardiovasc Med. 2021 Feb 03;7:629933. (PMID: 33614744) Clin Infect Dis. 2019 Aug 30;69(6):1036-1048. (PMID: 30508065) Ann Med Psychol (Paris). 2020 Sep;178(7):695-698. (PMID: 32836300) Mol Med Rep. 2020 Jul;22(1):9-19. (PMID: 32377709) J Virol. 2020 Aug 31;94(18):. (PMID: 32661141) Lancet Glob Health. 2021 Sep;9(9):e1216-e1225. (PMID: 34252381) Int J Infect Dis. 2021 Feb;103:316-322. (PMID: 33279652) PLoS One. 2015 Jun 11;10(6):e0128580. (PMID: 26068416) Allergy. 2021 Feb;76(2):428-455. (PMID: 33185910) Influenza Other Respir Viruses. 2019 Jan;13(1):3-9. (PMID: 30515985) Biomed Res Int. 2020 Sep 25;2020:7610678. (PMID: 33029522) Clin Infect Dis. 2012 Oct;55(7):996-1003. (PMID: 22715173) Open Forum Infect Dis. 2017 Feb 10;4(1):ofw262. (PMID: 28480255) Int Health. 2016 May;8(3):157-8. (PMID: 27178673) |
فهرسة مساهمة: | Keywords: COVID-19; HIV; pneumonia surveillance; pre-pandemic; risk factors; severe respiratory illness |
تواريخ الأحداث: | Date Created: 20240808 Latest Revision: 20240809 |
رمز التحديث: | 20240809 |
مُعرف محوري في PubMed: | PMC11304391 |
DOI: | 10.4102/sajid.v39i1.574 |
PMID: | 39114258 |
قاعدة البيانات: | MEDLINE |
تدمد: | 2313-1810 |
---|---|
DOI: | 10.4102/sajid.v39i1.574 |